JYJun Ye

Jun Ye

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jun Ye has a total of 43 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Human herpesvirus-6B infection leading to hemophagocytic lymphohistiocytosis in an adult: a case report

    by Ji Yuan, Jinjin Li, Lei Jin, Jun Ye, Zhenhua Zhang

    Hemophagocytic lymphohistiocytosis (HLH) secondary to human herpesvirus-6B (HHV-6B) infection is rare in immunocompetent adults. We report the case of a 43

  • Open Access

    A case of avian influenza A (H5N6) presented with secondary infection in Anhui Province, China, 2024

    by Wan-Rong Luo, Jun-Ling Yu, Yun Sun, Lei Gong, Sai Hou, Zhong-Hua Lu, Wei-Xi Fang, Hong-Ya Gui, Xue Zhou, Peng Wang, et al.


  • Open Access

    Fusobacterium nucleatum infection leading to rare hepatorenal abscess: a case report

    by Lei Jin, Changkang Chen, Hong Zhao, Lei Chen, Xian Wang, Qin Wang, Ji Yuan, Jinjin Li, Shen Xu, Runzhen Zhang, et al.

    Fusobacterium nucleatum is a gram-negative anaerobic bacterium commonly associated with periodontal disease. However, its role in extraoral infections, particularly in immunocompetent individuals, is increasingly recognized. We report a rare case of hepatorenal abscess caused by F. nucleatum in a previously healthy woman, initially suspected to have a malignant tumor based on PET-CT findings. Next-generation sequencing (NGS) of abscess aspirate confirmed the pathogen. The patient responded well to targeted antibiotic therapy. This case highlights the importance of considering anaerobic pathogens in deep-seated abscesses and the utility of NGS in achieving accurate microbial diagnosis.

  • Comparison of pharmacokinetics and safety of albuvirtide in healthy subjects after intravenous drip and bolus injection

    by Huiling Qin, Cheng Yao, Wei Zhang, Wei Hu, Yuantao Liu, Shuchang Yu, Dong Xie, Min Hu, Jun Ye

    Albuvirtide (ABT) is the first long-acting HIV fusion inhibitor developed in China, blocking the invasion of HIV-1 virus into target cells. This study aimed to compare the pharmacokinetics (PK), tolerability, and safety of ABT following a single intravenous (IV) bolus injection or intravenous drip in healthy Chinese subjects. A single-center, randomized, open-label, single-period, parallel phase I clinical trial was conducted. Thirty subjects were randomly divided into three groups in a ratio of 1:1:1. After an overnight fast, all subjects received a single dose of 320 mg ABT either by intravenous drip for 45 min (group A) or bolus injection for 0.5 min (group B), or bolus injection for 3 min (group C). ABT plasma concentrations were analyzed using a validated enzyme-linked immunosorbent assay (ELISA). Non-compartmental analysis was used to evaluate PK parameters. The median time to reach maximum concentration was 0.75 h in group A and 0.16 h in both groups B and C. Elimination half-life, mean residence time, apparent clearance, and apparent volume of distribution were similar among the three groups. The 90% confidence intervals (CI) of geometric mean ratios of PK parameters for groups B and C relative to group C were within 85–120%. All adverse events (AEs) reported in this study were mild, according to the CTCAE guidelines and the study investigator’s judgement. ABT bolus injections for 0.5 min and 3 min are expected to be well tolerated and to exhibit similar PK characteristics as IV drip for 45 min, offering potential clinical benefits.


  • Open Access

    Comparison of pharmacokinetics and safety of albuvirtide in healthy subjects after intravenous drip and bolus injection

    by Huiling Qin, Cheng Yao, Wei Zhang, Wei Hu, Yuantao Liu, Shuchang Yu, Dong Xie, Min Hu, Jun Ye

    Purpose. Albuvirtide (ABT) is the first long-acting HIV fusion inhibitor originally developed in China, blocking the invasion of HIV-1 virus into target cells. This study aimed to compare the pharmacokinetics, tolerability, and safety of ABT following a single intravenous (IV) bolus injection or intravenous drip in healthy Chinese subjects.Methods. A single-center, randomized, open-label, single-period, parallel phase I clinical trial was conducted. 30 subjects were randomly divided into 3 groups in a ratio of 1:1:1. After an overnight fast, all subjects received a single dose administration of 320 mg ABT by intravenous drip for 45 min (Group A) or bolus injection for 0.5 min (Group B) or bolus injection for 3 min (Group C). ABT plasma concentrations were analyzed using validated enzyme-linked immunosorbent assay. Noncompartmental analysis was used to evaluate PK parameters.Results. The median value of time to reach maximum concentration was 0.75 h in group A and 0.16 h in both group B and C, elimination half-life, mean residence time, apparent clearance and apparent volume of distribution was similar among three groups. The 90% confidence intervals of geometric mean ratios of PK parameters for group B and C relative to group C are mainly within 85–120%. All AEs in this study were mild, according to the CTCAE guidelines and the study investigator’s judgement.Conclusion. ABT bolus injection for 0.5 min and 3 min are expected well tolerated and to have similar pharmacokinetic characteristics as IV drip for 45 min, thus offering potential clinical benefits.